Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension

Abstract

Dapagliflozin reduces right ventricular systolic pressure and pulmonary vascular remodelling in a rat model of PAH. However, combination therapy with dapagliflozin and sildenafil was not more effective than monotherapy with sildenafil in PAH rats.